Calcineurin (protein phosphatase 3) regulates synaptic plasticity in the brain. The development of neuropathic pain appears dependent on some of the same mechanisms that underlie brain synaptic plasticity. In this study, we examined whether calcineurin regulates chronic constriction injury (CCI)-elicited plasticity in the spinal dorsal horn. CCI animals exhibited mechanical and thermal hypersensitivity 7 days after ligation of the sciatic nerve. Neither control uninjured nor sham-operated animals exhibited pain behavior. Calcineurin activity and content of its Aa isoform were significantly decreased in the ipsilateral postsynaptic density (PSD) of dorsal horn neurons in CCI animals. Calcineurin activity and content in the contralateral PSD of CCI animals or either side of the dorsal horn in sham animals were not modified. The pain behavior in CCI animals was attenuated by intrathecal application of exogenous calcineurin. The treatment was long-lasting as a single injection provided analgesia for 4 days by restoring the phosphatase's activity and Aa content in the PSD. No signs of toxicity were detected up to 14 days after the single intrathecal injection. Intrathecal application of the calcineurin inhibitor FK-506 elicited pain behavior in control uninjured animals and significantly reduced calcineurin activity in the PSD. CCI may elicit neuropathic pain at least in part as a result of the loss of calcineurin-mediated dephosphorylation in the dorsal horn. Addition of the phosphatase by intrathecal injection reverses the injury-elicited loss and provides prolonged pain relief. Clinical therapy with calcineurin may prove to be a novel, effective, and safe approach in the management of well-established neuropathic pain. Ó
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Introduction
Injury-elicited plasticity accompanies peripheral nerve injury to ultimately lead to the development of neuropathic pain [11, 18] . The development of neuropathic pain is dependent on some of the same mechanisms that give rise to activity-dependent synaptic plasticity in the brain [5] . Like synaptic plasticity, neuropathic pain exhibits early and late phases that may be mediated by different mechanisms [5, 11, 18] .
The balance between protein kinase and phosphatase activity at the synapse can critically determine overall synaptic strength [12] . As a result, the loss of either one of these activities can engender long-lasting changes in synaptic function, ie, long-lasting plasticity.
More than a decade ago, Kandel et al [1] described how the interplay between protein kinase A (PKA) and calcineurin (protein phosphatase 3, also protein phosphatase 2B) was essential in initiating and maintaining long-lasting enhancement of synaptic function in Aplysia, Drosophila, mice, and rats. Activation of PKA by cyclic adenosine monophosphate, and the subsequent phosphorylation of target proteins, resulted in long-term memory storage. In contrast, activation of calcineurin promoted the dephosphorylation of these target proteins to prevent the transition from short-to long-term memory.
Later studies confirmed the general role of calcineurin in negatively constraining the acquisition of spatial or aversive memory or of long-lasting plasticity in ocular dominance, cocaine addiction, and vestibular compensation [2,13,17,21,22].
Little is currently known about the role of calcineurin in injuryelicited plasticity in the spinal dorsal horn. Somatic and terminal immunoreactive staining for the phosphatase is heavy and highly restricted to the superficial dorsal horn [6, 20] . Terminal staining
